KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Equity Income (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 10 years of Equity Income data on record, last reported at -$57000.0 in Q4 2025.

  • For Q4 2025, Equity Income fell 256.25% year-over-year to -$57000.0; the TTM value through Dec 2025 reached -$405000.0, up 75.6%, while the annual FY2025 figure was -$732000.0, 55.9% up from the prior year.
  • Equity Income reached -$57000.0 in Q4 2025 per JAZZ's latest filing, down from -$47000.0 in the prior quarter.
  • Across five years, Equity Income topped out at $4.2 million in Q1 2021 and bottomed at -$4.1 million in Q1 2022.
  • Average Equity Income over 5 years is -$856000.0, with a median of -$617000.0 recorded in 2022.
  • The widest YoY moves for Equity Income: up 2188.46% in 2021, down 422.63% in 2021.
  • A 5-year view of Equity Income shows it stood at -$3.0 million in 2021, then soared by 74.13% to -$773000.0 in 2022, then soared by 40.36% to -$461000.0 in 2023, then surged by 96.53% to -$16000.0 in 2024, then plummeted by 256.25% to -$57000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Income were -$57000.0 in Q4 2025, -$47000.0 in Q3 2025, and -$16000.0 in Q4 2024.